161 related articles for article (PubMed ID: 2659170)
21. Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer.
Zangemeister-Wittke U; Collinson AR; Fisch I; Jones RM; Waibel R; Lehman HP; Stahel RA
Int J Cancer; 1993 Jul; 54(6):1028-35. PubMed ID: 8392978
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin.
Collinson AR; Lambert JM; Liu Y; O'Dea C; Shah SA; Rasmussen RA; Goldmacher VS
Int J Immunopharmacol; 1994 Jan; 16(1):37-49. PubMed ID: 8150554
[TBL] [Abstract][Full Text] [Related]
23. Application of anti-sialyl Lea monoclonal antibody, KM231, for immunotherapy of cancer.
Shitara K; Hanai N; Kusano A; Furuya A; Yoshida H; Wada K; Watanabe T; Sato S
Anticancer Res; 1991; 11(6):2003-13. PubMed ID: 1776833
[TBL] [Abstract][Full Text] [Related]
24. In vivo studies of whole ricin monoclonal antibody immunoconjugates for the treatment of murine tumours.
Kanellos J; MacKenzie IF; Pietersz GA
Immunol Cell Biol; 1988; 66 ( Pt 5-6)():403-15. PubMed ID: 3265693
[TBL] [Abstract][Full Text] [Related]
25. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Ramakrishnan S; Bjorn MJ; Houston LL
Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
27. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
28. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
Engert A; Martin G; Amlot P; Wijdenes J; Diehl V; Thorpe P
Int J Cancer; 1991 Sep; 49(3):450-6. PubMed ID: 1917143
[TBL] [Abstract][Full Text] [Related]
29. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
Blakey DC; Watson GJ; Knowles PP; Thorpe PE
Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
[TBL] [Abstract][Full Text] [Related]
30. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
Grossbard ML; Lambert JM; Goldmacher VS; Blättler WA; Nadler LM
Cancer Res; 1992 Aug; 52(15):4200-7. PubMed ID: 1379121
[TBL] [Abstract][Full Text] [Related]
31. Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.
Rasmussen RA; Counts SL; Lambert JM; Collinson AR
Cancer Immunol Immunother; 1992; 35(5):355-63. PubMed ID: 1394340
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
Calvete JA; Newell DR; Wright AF; Rose MS
Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
[TBL] [Abstract][Full Text] [Related]
34. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
35. Analysis of gp74 expression by transformed rat fibroblasts from experimental pulmonary metastases following specific ricin A-chain immunotoxin therapy.
Roth JA; Thomsen S; Fry KD; Scannon P; Chang C
Cancer Res; 1989 Oct; 49(20):5708-12. PubMed ID: 2676148
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody 45-2D9 conjugated to the A chain of ricin is specifically toxic to c-Ha-ras-transfected NIH 3T3 cells expressing gp74.
Roth JA; Ames RS; Byers V; Lee HM; Scannon PJ
J Immunol; 1986 Mar; 136(6):2305-10. PubMed ID: 3950414
[TBL] [Abstract][Full Text] [Related]
37. Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin.
Bourrie BJ; Casellas P; Blythman HE; Jansen FK
Eur J Biochem; 1986 Feb; 155(1):1-10. PubMed ID: 3948873
[TBL] [Abstract][Full Text] [Related]
38. Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates.
Thiesen HJ; Juhl H; Arndt R
Cancer Res; 1987 Jan; 47(2):419-23. PubMed ID: 3539323
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
FitzGerald DJ; Bjorn MJ; Ferris RJ; Winkelhake JL; Frankel AE; Hamilton TC; Ozols RF; Willingham MC; Pastan I
Cancer Res; 1987 Mar; 47(5):1407-10. PubMed ID: 3493065
[TBL] [Abstract][Full Text] [Related]
40. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.
Goldmacher VS; Bourret LA; Levine BA; Rasmussen RA; Pourshadi M; Lambert JM; Anderson KC
Blood; 1994 Nov; 84(9):3017-25. PubMed ID: 7524764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]